It is with our deepest sorrow that we announce the passing of our beloved friend and co-founder, Patricia.
In < 2 years of our foundation, we lost 3 of our founding advocates. All diagnosed well below screening age.
Please help us to keep her legacy alive
change.org/p/lower-the-ag…

1/2 Excited to launch this pan🇨🇦 ph. 2 RCT of FMT+ICI in melanoma with the CCTG J. Lenehan Janet Dancey Saman Maleki, PhD. Thanks to the Canadian Cancer Society Weston Family Foundation we will understand the mechanism of FMT to unlock the next gen of microbiome therapeutics Bertrand Routy MD,PhD

“Immune Checkpoint Inhibitor Therapy in Locally Advanced MSI GI Malignancies” by Emily C. Harrold, MB, BCh, BA); Fergus Keane, MB, BCh, BAO; and Andrea Cercek, MD hematologyandoncology.net/archives/may-2… Emily Harrold Andrea Cercek Memorial Sloan Kettering Cancer Center

April is #BowelCancerAwarenessMonth

As we work towards developing bowel cancer treatment, the MOUNTAINEER-03 clinical trial is open at all 3 of our CTG sites: Bon Secours Cork Cancer Centre I Cork University Hospitals I Univ Hosp Waterford

Nice editorial in JAMA Oncology today urging caution in pts w near CR after total neoadjuvant therapy in rectal cancer.

Reported rates of conversion from nCR to cCR vary widely from 39% to 100%!

Completely agree these patients should be counseled re: uncertainty of pursuing organ

Can't agree more! Blood-based CRC screening? Cool, but a long way to go:
1.Too💲 🆚 FIT
2.Low sens. for adenomas 🆚FIT/scopes
3.🚨60% FIT/scopes participation still more cost-effective than 100% participation with cfDNA!

#GetScreened #CRCAwareness

gastrojournal.org/article/S0016-…

SO glad to see this out! CRITICAL information from Journal of Clinical Oncology Nuh Rahbari Florian Lordick.
🛑 The PRIMARY #COLORECTAL tumor should NOT be resected unless needed
🛑 NO diff in OS. #cancer #crcsm #CancerResearch #clinicaltrials Vanderbilt Hem / Onc Vanderbilt-Ingram Cancer Center

Precision medicine for #PancreaticCancer : Characterizing the clinico-genomic landscape and outcomes of KRAS G12C-mutated disease
In JNCI from Wungki Park, MD MS Eileen M O’Reilly Rona Yaeger & colleagues Memorial Sloan Kettering Cancer Center
~1% of pancreatic cancers harbor G12C and may have a

Primary Tumor Resection Before Systemic Therapy in CRC & Unresectable Metastases
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
🔎SYNCHRONOUS & CCRe-IV; 2011 - 2017, 393 pts
🚫No survival benefit for resection of the primary tumor at baseline
🧐24% in the PTR group no CTx
🤨overall

Scan QR code to download your copy of the new patient guide to #BowelCancer in Ireland. Useful to all as contains important information on symptoms & screening - something everyone needs to be aware of! #BowelCancer AwarenessMonth RCSI PPI Ignite HealthResearchBoard

Are ICIs safe in pts with solid organ transplant? Multicentre retrospective study Jordi Remon ESMO Open:

- 31pts (98% kidney, 36% NSCLC)
- irAEs➡️ICI stop 12.9%
- rejection rate 25.8% (mono 28% combo 33% p NS)

A privilege to review this paper OncoAlert
sciencedirect.com/science/articl…

📢📢📢Kind reminder 👇

Watch first author Rona Yaeger discuss her research article, Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated #Metastatic #ColorectalCancer , published simultaneously at #AACR24 :
vimeo.com/932606282/f27a…
Memorial Sloan Kettering Cancer Center

#ClinicalTrial EA2222/PUMP, led by Michael Lidsky, MD, FACS, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: bit.ly/ea2222-pump cc: Michael D’Angelica, Shishir K. Maithel, Andrea Cercek

New #JITC position article and guidelines: Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy bit.ly/3PZVxNM Steven Chen 陳持威, MD, MPH, MHPEd Eugene Semenov, MD Allison Betof Warner, MD, PhD Jarushka Naidoo Kerry Reynolds